Drugs / Ifebemtinib
Trials 19 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT07652762 | Jun 2026 → Aug 2028 expected | CDK4 linked melanoma, meningioma | Capital Medical University | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06946927 | Jun 2025 → Feb 2026 overdue | non-small cell lung carcinoma | Jemincare | Recruiting | No outcome recorded |
| Phase 1 | NCT05327231 | Jul 2020 → Dec 2021 | gastric cancer | InxMed (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04109456 | Mar 2020 → Dec 2024 | metastatic melanoma | InxMed (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT01905111 | Jul 2013 → Aug 2014 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1 | NCT01335269 | Jul 2011 → Sep 2015 | neoplasm | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase 1/210 trials | ||||||
| Phase 1/2 | NCT07441174 | Feb 2026 → Feb 2031 expected | pancreatic ductal adenocarcinoma | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05982522 | Aug 2025 → Dec 2026 | neoplasm | InxMed (Shanghai) Co., Ltd. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06708663 | Jan 2025 → Dec 2027 expected | biliary tract cancer, melanoma | Hangzhou Hanx Biopharmaceuticals, Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06030258 | Oct 2023 → Dec 2025 overdue | small cell lung carcinoma | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05994131 | Jul 2023 → Jul 2026 overdue | non-small cell lung carcinoma | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05827796 | Dec 2022 → Dec 2025 overdue | malignant pancreatic neoplasm | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06166836 | Oct 2022 → Dec 2027 expected | neoplasm | InxMed (Shanghai) Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05379946 | Oct 2022 → Dec 2027 expected | cancer | InventisBio Co., Ltd | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05830539 | Mar 2022 → Aug 2024 | — | InxMed (Shanghai) Co., Ltd. | Completed | No outcome recorded |
| Phase 1/2 | NCT05551507 | Jul 2020 → May 2026 overdue | refractory malignant neoplasm | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06654011 | Feb 2025 → May 2026 overdue | endocervical adenocarcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | No outcome recorded |
| Phase 2 | NCT06014528 | Sep 2022 → Dec 2026 expected | ovarian carcinoma | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07174908 | Sep 2025 → Sep 2028 expected | non-small cell lung carcinoma | InxMed (Shanghai) Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ifebemtinib | “Ifebemtinib, a potent selective oral inhibitor of FAK, has shown preclinical synergistic activity with KRASG12C inhibitors.” PMID 42413526 ↗ Jul 2026 |
| Known as | BI 853520 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01335269 ↗ |
| Known as | IN10018 | “Ifebemtinib (IN10018) is an investigational oral focal adhesion kinase inhibitor.” NCT07652762 ↗ |
| Action | Inhibit | “BI 853520, a novel, potent, highly selective FAK inhibitor.” PMID 30756308 ↗ Feb 20191“Focal adhesion kinase 1 inhibitor” CHEMBL3657311 ↗ |
| Modality | Small molecule | — CHEMBL3657311 ↗ |
| Route | Oral | “Administered Orally” NCT01335269 ↗ |
| Target | PTK2 | “Focal adhesion kinase 1 inhibitor” CHEMBL3657311 ↗ |